THE EFFECT OF RECOMBINANT VASCULAR ENDOTHELIAL GROWTH FACTOR 121 ON NITRIDE OXIDE LEVEL IN MICE (Mus musculus) MODEL OF PREECLAMPSIA

Soetrisno Soetrisno, Isharyadi Isharyadi, Sri Sulistyowati

= http://dx.doi.org/10.20473/fmi.v53i3.6446
Abstract views = 569 times | downloads = 471 times

Abstract


Preeclampsia is a multifactorial syndrome in pregnancy whose cause is still unknown. Several proangiogenic and antiangiogenic mediators such as Vascular Endothelial Growth Factor (VEGF) and Nitrite Oxide (NO) play important roles in preventing preeclampsia. VEGF can increase NO level that lowers maternal blood pressure, improves endothelial function and reduces placental hypoxia in preeclampsia. Recombinant VEGF 121 is expected to be an option in the prevention and treatment of preeclampsia. This experimental study used mice (Mus musculus) as the model. The objective of this study was to observe the effect of recombinant VEGF 121 in increasing the level of nitric oxide in mice (Mus musculus) model of preeclampsia. This was an experimental analytical study with Randomized Control Trial (RCT) design. The study enrolled 27 pregnant mice (Mus musculus) which met the restriction criteria divided into 3 groups. The first group (K1) were 9 normal pregnant mice. The second group (K2) were 9 pregnant mice of preeclampsia model without treatment. The third group (K3) were 9 pregnant mice of preeclampsia model receiving recombinant VEGF 121 therapy. The independent variable was the administration of recombinant VEGF 121 and the dependent variable was the serum NO level. Statistical analysis was performed by using anova statistics. NO level in the first group (K1) was 1.746±0.347, with minimum value of 1.00 µM, and maximum value of 2.28 µM, CI (1.479-2.013).  NO level in second group (K2) was 1.167±0.380, with minimum value of 0.64 µM, and maximum value of 1.94 µM, CI (0.875-1.460). NO level in the third group (K3) was 2.164±0.556, with minimum value of 1.56 µM, and maximum value of 5.96 µM, CI (1.842-2.486). With anova statistical test, there were significant differences between K1 group and K2 group (p value=0.004<0.05), K1 group and K3 group (p value=0.000<0.05) as well as K2 group and K3 group (p value=0.029<0.05). In conclusion, Recombinant VEGF 121 increased the level of nitric oxide in mice (Mus musculus) model of preeclampsia significantly.

Keywords


Recombinant Vascular Endothelial Growth Factor 121; nitric oxide; mice (Mus musculus); preeclampsia

Full Text:

PDF

References


Anggraini ND (2015). The effect of recombinant VEGF 121 on histopathological image changes of placenta and fetal weight in mice (Mus musculus) model of preeclampsia

Comiskey M, Warner CM, Schust DJ (2013). MHC molecules of the preimplantation embryo and tropho-blast. Available from http://www.ncbi.nlm.nih. gov/books/NBK6277/. Published 2013. Accessed September 21, 2016

Damayanti PD, Sulistyowati S, Respati SH (2015). Differences of endothelin-1 serum (ET-1) and nitrit oxide (NO) among preeclmapsia late onset and and normal pregnancy. Obstetrics and Gynecology of Medical Faculty UNS/DR Moewardi Hospital Surakarta

Duley L (2009). the global impact of pre-eclampsia and eclampsia. Semin Perinatol 33, 130-137. doi: 10.1053 /j.semperi.2009.02.010.

Erdemoglu E, Ugur M and Erdemoglu E (2009). Plasma homocysteine and nitric oxide level in preeclampsia. Dep Obstet Gynecol Zekai Tahir Burak Women Heal Res Educ Hosp Ankara, Turkey A Turkish-German Gynecol Assoc; 10 26-9

Hladunewich, Karumanchi L (2007). Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol 2, 543-549. doi: 10.2215 / CJN.03761106.

Irawan D, Sulistyowati S, Edwin E, Obstetrics D (2016). Recombinant VEGF 121 can improve glome-rular endothelosis in pregnant mice model of Preeclampsia. Maj Ginekol Obstet, 24

Li Z, Zhang Y, Ma JY, et al (2007). Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50, 686-92

Markham KB, Funai EF (2014). Pregnancy-related hypertension classification of hypertensive disorders. In: Robert K. Creasy, Robert Resnik, Michael F. Greene, Jay D. Iams CJL, Thomas R. Moore, eds. Creasy and Resnik's Maternal-fetal medicine: principles and practice, China, Elsevier Saunders, p 756-781

Nakagawa T (2007). Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol 292, F1665-F1672. doi: 10.1152/ajprenal.00495.2006

Naljayan MV, Karumanchi SA (2013). New developments in the pathogenesis of preeclampsia. Adv Chronic Kidney Dis 20, 265-270

Nirwanasari R, Sulistyowati S, Respati SH (2014). Intra uterine growth restriction: the role of vascular endothelial growth factor (VEGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in its Pathogenesis, Surakarta, Universitas Sebelas Maret

Prabowo W (2015). Effect of recombinant VEGF 121 on placenta growth factor (PlGF) in mice (Mus musculus) model of preeclampsia

Roswendi A, Sulistyowati S, Respati SH, Kartika H (2014). Level of soluble human leukocyte antigen-G (sHLA-G), vascular endothelial growth factor (VEGF) and soluble fms-like tyrosin kinase-1 (sFlt-1) in preeclampsia . Maj Ginekol Obstet 22

Saha T, Halder M, Das A, Das SK (2013). Role of nitric oxide, angiogenic growth factors and biochemical analysis in preeclampsia 50 462-466

Schlembach D (2003). Preeclampsia - still a disease of theories. Fukushima J Med Sci 49, 69-115.

Shah DM (2007). Preeclampsia: new insights. Curr Opin Nephrol Hypertens 16, 213-220

Sibai BM. Preeclampsia and hypertensive disorders of pregnancy. In: Steven G. Gabbe, Jennifer R. Niebyl, Joe Leigh Simpson MD, Mark B. Landon MD, Henry L. Galan MD, Eric RM Jauniaux MD, PhD, Deborah A. Driscoll MD, Vincenzo Berghella MD and William A. Grobman MD M, ed. Elsevier Inc. Seventh Ed. Philadelphia: Elsevier Inc. 661-705. doi: 10.1016 / B978-0-323-32108-2.00031-7

Sondakh JA, Sulistyowati S, Respati SH (2016). Recombinant vascular endothelial growth factor 121 decreases vascular cell adhesion molecule-1 in murine pre-eclampsia placenta model. Universa Med 35

Steinberg G, Khankin E V., Karumanchi SA (2011). Angiogenic factors and preeclampsia. Semin Nephrol 31, 33-46. doi: 10.1016 / S0049-3848 (09) 70020-9.

Sulistyowati S, Bachnas MA, Anggraini ND, et al (2017). Recombinant vascular endothelial growth factor 121 injection for the prevention of fetal growth restriction in a preeclampsia mouse model. J Perinat Med 45, 245–51. doi: 10.1515/jpm-2016-0149

Wiyono BE, Sulistyowati S, Respati SH (2015). Angiogenic Factors Soluble FMS-Like Tyrosine Kinase-1 and Vascular Endothelial Growth Factor in Pregnant Women of 8-20 Gestational Weeks with Risk of Preeclampsia. J Kesehatan Reproduksi 2

Woods AK, Hoffmann, Weydert, Butler, Zhou, Sharma (2011). Adenoviral delivery of VEGF 121 early in pregnancy prevents spontaneous development of pre-eclampsia in BPH / 5 Mice. Hypertension.2011 Jan; 57 (1): 94-102. Hypertension 57, 94-102


Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Soetrisno Soetrisno, Isharyadi Isharyadi, Sri Sulistyowati

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Indexed By

View My Stats

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.